Mesalazine granules are superior to Eudragit-L-coated mesalazine tablets for induction of remission in distal ulcerative colitis - a pooled analysis

Leifeld, Ludger; Pfützer, Roland H.; Morgenstern, J; Gibson, Peter R.; Marakhouski, Y; Greinwald, Roland; Müeller, Ralph; Kruis, Wolfgang

doi:10.1111/j.1365-2036.2011.04840.x

Cited by 32 publications

(17 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Less frequent dosing may improve medication adherence in ulcerative colitis as is seen with other chronic disease states, such as hypertension [7,8] and diabetes [9,10]. The benefits of less frequent medication administration on medication adherence and clinical outcomes have been demonstrated with mesalamine products traditionally dosed more frequently [11][12][13]. The overall low levels of medication adherence in our study are consistent with other retrospective claims database evaluations [14].…”

Section: Discussionsupporting

confidence: 86%

Adherence to 5-Aminosalicylic Acid Treatment in Ulcerative Colitis

Love¹,

Johnson²,

Jw³

et al. 2015

J Hepatol Gastroint Dis

View full text Add to dashboard Cite

Background: Oral 5-aminosalicylic acid (5-ASA) therapy is the first choice therapy for ulcerative colitis (UC), and adherence to therapy is important for long-term clinical improvement. Objective: To assess the relationship between dosing frequency, pill burden, clinical outcomes and medication adherence in patients receiving various 5-ASA formulations. Methods: A single center, cross-sectional study was conducted in outpatients diagnosed with ulcerative colitis and prescribed aminosalicylates during a 3.5 year period. Medication adherence was quantified using the medication possession ratio (MPR), and non-adherence was defined as taking less than 80% of the prescribed dose. Demographic data, 5-ASA medication fill history and treatment outcomes data were collected. Clinical outcomes were assessed including surgery, hospitalization, emergency department (ED) visit, and documented flares. Logistic regression was used to model the odds of adherence to 5-ASA based on medication and dosing frequency. Results: Non-adherence was observed in 66 (52.4%) of the 126 enrolled subjects. The median adherence rate in all patients was 78.2% (IQR 39.3). Most patients received either balsalazide (38.9%) or mesalamine delayed release (DR) tablets [Asacol ® ] (31.8%). Very few subjects received 5-ASA once or twice daily (25.4%). Significant differences were observed between dosing frequency and daily pill burden when comparing "adherent" and "nonadherent"patients. Patients receiving mesalamine MMX [Lialda ® ], mesalamine DR, and sulfasalazine were more likely to be adherent compared to balsalazide. No significant association was noted between clinical outcomes and medication adherence. Conclusion: Overall, medication non-adherence was common in this sample of patients. Less frequent dosing and choice of 5-ASA were associated with medication adherence in adjusted models.

show abstract

Section: Discussionsupporting

confidence: 86%

Adherence to 5-Aminosalicylic Acid Treatment in Ulcerative Colitis

Love¹,

Johnson²,

Jw³

et al. 2015

J Hepatol Gastroint Dis

View full text Add to dashboard Cite

show abstract

“…Ein direkter Vergleich zu 5-ASA liegt jedoch nicht vor. Für dieses Befallsmuster scheint die Einnahme eines 5-ASA-Granulats günstig [247].…”

Section: Hintergrundunclassified

“…Eine Alternative zur rektalen Applikation bei distaler Colitis und geringer Therapieadhärenz können 5-Aminosalizylat-Formulierungen der neueren Generation (bspw. Multimatrix-Formulierungen, Granula) mit gutem Freisetzungsprofil im linksseitigen Colon sein; sie sind den Aminosalizylaten älterer Generation mit ilealer Freisetzung in diesem Fall überlegen [247,273,274].…”

Section: Hintergrundunclassified

Aktualisierte S3-Leitlinie Colitis ulcerosa der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS)

2018

Z Gastroenterol

View full text Add to dashboard Cite

This guideline provides evidence-based key recommendations for diagnosis and treatment of ulcerative colitis and upgrades the 2011 version. The guideline was developed by an interdisciplinary team of gastroenterologists, surgeons, pathologists, nutrition experts, and patient support groups under the auspice of the German Society for Gastroenterology and Metabolic Diseases. The guideline used structural S3 consensus-based methodology and includes statements on clinical practice, prevention, infectiological problems, surgery and nutrition.

show abstract

“…A direct comparison with mesalazine is, however, lacking. For this disease localisation, intake of mesalazine granules appears beneficial [247].…”

Section: Introductionmentioning

confidence: 99%

Updated S3-Guideline Ulcerative Colitis. German Society for Digestive and Metabolic Diseases (DGVS)

2019

Z Gastroenterol

View full text Add to dashboard Cite

show abstract

Mesalazine granules are superior to Eudragit-L-coated mesalazine tablets for induction of remission in distal ulcerative colitis - a pooled analysis

Abstract: SUMMARY BackgroundDifferent oral formulations of 'mesalazine (mesalamine)' may have different efficacy in distal ulcerative colitis.

Cited by 32 publications

References 24 publications

Adherence to 5-Aminosalicylic Acid Treatment in Ulcerative Colitis

Adherence to 5-Aminosalicylic Acid Treatment in Ulcerative Colitis

Aktualisierte S3-Leitlinie Colitis ulcerosa der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS)

Updated S3-Guideline Ulcerative Colitis. German Society for Digestive and Metabolic Diseases (DGVS)

Contact Info

Product

Resources

About